Cargando…

Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization

PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12...

Descripción completa

Detalles Bibliográficos
Autores principales: Haubold, Johannes, Ludwig, Johannes M., Li, Yan, Buechter, Matthias, Wetter, Axel, Umutlu, Lale, Theysohn, Jens M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988944/
https://www.ncbi.nlm.nih.gov/pubmed/31995589
http://dx.doi.org/10.1371/journal.pone.0227972
_version_ 1783492336277258240
author Haubold, Johannes
Ludwig, Johannes M.
Li, Yan
Buechter, Matthias
Wetter, Axel
Umutlu, Lale
Theysohn, Jens M.
author_facet Haubold, Johannes
Ludwig, Johannes M.
Li, Yan
Buechter, Matthias
Wetter, Axel
Umutlu, Lale
Theysohn, Jens M.
author_sort Haubold, Johannes
collection PubMed
description PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated. RESULTS: Patients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings. CONCLUSION: After cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies.
format Online
Article
Text
id pubmed-6988944
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-69889442020-02-04 Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization Haubold, Johannes Ludwig, Johannes M. Li, Yan Buechter, Matthias Wetter, Axel Umutlu, Lale Theysohn, Jens M. PLoS One Research Article PURPOSE: The purpose of this study is to evaluate the use of density measurements in the diagnosis of an underlying residual tumor beyond iodine depositions after Lipiodol-based conventional transarterial chemoembolization (cTACE). METHOD AND MATERIALS: Thirty follow-up CT scans of 20 patients 6–12 weeks after Lipiodol-based cTACE, receiving a digital subtraction angiography at the same time, were analyzed. Reference for the detection of a residual tumor was the angiography, and a visible contrast enhancement was categorized as a residual tumor (n = 16 with residual tumor; n = 14 without residual tumor). The density of the iodine depositions was measured in all containing slices in non-contrast-, arterial- and portal venous-phase CT scans, with a slice thickness of 5.00 mm. The mean density of the iodine deposition during the portal venous phase was subtracted from the mean density of the arterial phase to calculate the density changes (a positive enhancement score represents washout in the portal venous phase). In addition, a quotient relating to the non-contrast measurement was evaluated. RESULTS: Patients with a residual tumor displayed significantly higher enhancement scores in favor of density reduction between the arterial and portal venous phases, compared to patients without a residual tumor (1.41 ± 3.59, n = 14 vs. -13.97 ± 2.88, n = 16; p-value < 0.01). Furthermore, 87.75% of patients with an enhancement score higher than -1.00 (n = 9) had a residual tumor, whereas 100.00% of patients with an enhancement score lower than -20.00 (n = 6) were shown to be tumor-free. The enhancement score quotient resulted in similar findings. CONCLUSION: After cTACE in patients with hepatocellular carcinoma (HCC), the presence of a viable tumor correlated with enhancement scores based on the density measurements of iodine depositions in different phases of the CT scan. Low enhancement scores were associated with completely treated tumors and can aid the decision process to avoid possibly unnecessary angiographies. Public Library of Science 2020-01-29 /pmc/articles/PMC6988944/ /pubmed/31995589 http://dx.doi.org/10.1371/journal.pone.0227972 Text en © 2020 Haubold et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Haubold, Johannes
Ludwig, Johannes M.
Li, Yan
Buechter, Matthias
Wetter, Axel
Umutlu, Lale
Theysohn, Jens M.
Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title_full Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title_fullStr Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title_full_unstemmed Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title_short Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization
title_sort measuring the density of iodine depositions: detecting an invisible residual tumor after conventional transarterial chemoembolization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988944/
https://www.ncbi.nlm.nih.gov/pubmed/31995589
http://dx.doi.org/10.1371/journal.pone.0227972
work_keys_str_mv AT hauboldjohannes measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT ludwigjohannesm measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT liyan measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT buechtermatthias measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT wetteraxel measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT umutlulale measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization
AT theysohnjensm measuringthedensityofiodinedepositionsdetectinganinvisibleresidualtumorafterconventionaltransarterialchemoembolization